Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $7.00.

PGEN has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th.

Precigen Stock Down 4.8 %

PGEN stock opened at $1.77 on Tuesday. The company has a market capitalization of $518.38 million, a price-to-earnings ratio of -3.22 and a beta of 1.58. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17. The firm has a 50 day moving average of $1.50 and a two-hundred day moving average of $1.11.

Institutional Trading of Precigen

Several large investors have recently modified their holdings of the company. Envestnet Asset Management Inc. boosted its holdings in shares of Precigen by 29.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after buying an additional 5,915 shares during the period. Invesco Ltd. boosted its holdings in shares of Precigen by 14.6% during the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock worth $53,000 after buying an additional 6,040 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Precigen by 26.6% during the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after buying an additional 10,900 shares during the period. Stoneridge Investment Partners LLC boosted its holdings in shares of Precigen by 21.3% during the 4th quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after buying an additional 12,063 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Precigen by 12.0% during the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock worth $128,000 after buying an additional 12,285 shares during the period. 33.51% of the stock is owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.